{
    "topic": "opioid_crisis",
    "source": "The Guardian",
    "bias": 0,
    "url": "https://www.theguardian.com/us-news/2019/jan/24/fda-opioids-big-pharma-prescriptions",
    "title": "FDA's opioids adviser accuses agency of having 'direct' link to crisis",
    "date": "2019-01-24",
    "authors": "Chris Mcgreal",
    "content": "The Food and Drug Administration is sacrificing American lives by continuing to approve new high-strength opioid painkillers , and manipulating the process in favor of big pharma , according to the chair of the agency \u2019 s own opioid advisory committee .\nDr Raeford Brown told \u2588\u2588\u2588 there is \u201c a war \u201d within the FDA as officials in charge of opioid policy have \u201c failed to learn the lessons \u201d of the epidemic that has killed hundreds of thousands of people over the past 20 years and continues to claim about 150 lives a day .\nBrown accused the agency of putting the interests of narcotics manufacturers ahead of public health , most recently by approving a \u201c terrible drug \u201d , Dsuvia , in a process he alleged was manipulated .\n\u201c They should stop considering any new opioid evaluation , \u201d said Brown . \u201c For every day and every week and every month that the FDA don \u2019 t do the right thing , people drop dead on the streets . What they do has a direct impact on the mortality rate from opioids in this country . \u201d\nBrown , an anesthesiologist who chairs the FDA committee of specialists advising the agency on whether to approve new opioid painkillers , said he no longer had confidence in repeated assurances by the FDA leadership that it was taking the epidemic seriously and prepared to put public health above the commercial interests of drug makers .\nUS regions where drug companies marketed hit hardest by opioids crisis Read more\n\u201c I think that the FDA has learned nothing . The modus operandi of the agency is that they talk a good game and then nothing happens . Working directly with the agency for the last five years , as I sit and listen to them in meetings , all I can think about is the clock ticking and how many people are dying every moment that they \u2019 re not doing anything , \u201d he said . \u201c The lack of insight that continues to be exhibited by the agency is in many ways a willful blindness that borders on the criminal . \u201d\nBrown \u2019 s comments echo criticisms by US senators who have condemned the FDA for what they say is its \u201c complicity \u201d in the epidemic , for approving the powerful painkillers that drove the crisis and then failing to use its powers to protect the public as the death toll escalated .\nFour US senators wrote to the head of the FDA , Dr Scott Gottlieb , late last year urging him not to allow Dsuvia , a powerful opioid pill , on to the market because it was \u201c to the detriment of public health \u201d .\nDsuvia is a branded narcotic sufentanil pill , a more potent version of fentanyl , made by Californian pharmaceutical company AcelRx . The signatories included Senator Joe Manchin of West Virginia , whose state has the highest rate of opioid overdose deaths in the country .\n\u201c This puzzling and unacceptable course of events is unfortunately reminiscent of previous FDA processes and practices that contributed to the opioid epidemic , \u201d the letter said .\nThe FDA \u2019 s credibility has been badly damaged by the opioid crisis amid accusations that at times it behaved less as a regulator overseeing the pharmaceutical industry than a business partner of drug manufacturers . The agency helped unleash the epidemic two decades ago when it approved the sale of a high strength narcotic pill , OxyContin , as safer and more effective than other painkillers on the say so of the manufacturer , Purdue Pharma , and without requiring clinical trials . Since then the FDA has approved other opioids for wide prescribing even as evidence mounted the drugs were addictive , open to abuse and often not effective for long-term use .\nThe FDA was also embarrassed by revelations that officials responsible for opioid approvals were taking part in \u201c pay to play \u201d schemes in which manufacturers paid to attend meetings to draw up the criteria for approving prescription narcotics .\nDonald Trump \u2019 s opioid commission identified the failure of the FDA and other federal institutions to properly regulate opioids and their manufacturers as an important factor in the epidemic .\nAfter Trump appointed Gottlieb , the new FDA chief admitted the agency \u201c didn \u2019 t get ahead \u201d of the crisis and promised \u201c dramatic \u201d action . He said he favoured examining not only whether an opioid worked but whether it was needed and whether the risks of it feeding the epidemic outweighed benefits for patients .\nBut that commitment has been called into question by the slow pace of introducing new practices and regulations \u2013 and by the approval of Dsuvia , a potent pill developed with the US defense department .\nAn advisory committee rejected the drug in 2017 over safety concerns . The senators said that they were \u201c deeply troubled \u201d that when Dsuvia was resubmitted for consideration the following year , the FDA excluded members of the agency \u2019 s drug safety committee from the hearing . The senators also said they were concerned because the decision was made when Brown , a strong critic of Dsuvia , was absent at a professional conference in San Francisco .\n\u201c There \u2019 s no question in my mind right that they did that on purpose , \u201d he said . \u201c The FDA has a lack of transparency . They use the advisory committees as cover . \u201d\nThe FDA is not required to follow the decisions of its advisory committees but has been wary of going against their decisions since 2012 , when the agency created a political storm by overruling a decision to reject Zohydro , an opioid 10 times more powerful than regular painkillers .\nDoctors and specialists on the committee questioned the safety of the drug and the need for it given the epidemic . The senior FDA official at the hearing , Dr Bob Rappaport , who was head of the agency \u2019 s opioid approval division , angered other members by telling them there had to be \u201c a level playing field for business \u201d , which was widely interpreted as putting the right of pharmaceutical companies to make money ahead of public health .\nBrown described a breakdown in confidence and trust between his advisory committee and FDA officials responsible for opioid approvals . He characterized them as out of touch with the consequences of the epidemic and locked into a view promoted by drugmakers that those who become hooked are to blame for their addiction not the pills or prescribing practices .\nBrown blamed the problem in part on \u201c cozy , cozy relationships between the pharmaceutical industry and various parts of the FDA \u201d . Since a change to the FDA \u2019 s funding in the 1990s , the agency division responsible for opioid approvals relies on the drug industry for 75 % of its budget . The agency denies the money buys influence .\nGottlieb has previously defended Dsuvia by saying it is required for use in circumstances where other drugs can not be administered , such as a battlefield . The FDA chief promised \u201c very tight restrictions \u201d on its distribution to stop the drug appearing on the illicit market . He insisted the FDA had \u201c learned much from the harmful impact \u201d that prescription opioids have had .\n\u201c Nothing is fundamentally being done to effect change in the regulation of opioids . If the FDA continues to encourage the pharmaceutical industry to turn out opioid after opioid after opioid , and the regulation of those opioids is no better than it was in 1995 , then we \u2019 ll be cleaning this up for a long time , \u201d said Brown .\nChris McGreal is the author of American Overdose : The Opioid Tragedy in Three Acts",
    "content_original": "The Food and Drug Administration is sacrificing American lives by continuing to approve new high-strength opioid painkillers, and manipulating the process in favor of big pharma, according to the chair of the agency\u2019s own opioid advisory committee.\n\nDr Raeford Brown told the Guardian there is \u201ca war\u201d within the FDA as officials in charge of opioid policy have \u201cfailed to learn the lessons\u201d of the epidemic that has killed hundreds of thousands of people over the past 20 years and continues to claim about 150 lives a day.\n\nBrown accused the agency of putting the interests of narcotics manufacturers ahead of public health, most recently by approving a \u201cterrible drug\u201d, Dsuvia, in a process he alleged was manipulated.\n\n\u201cThey should stop considering any new opioid evaluation,\u201d said Brown. \u201cFor every day and every week and every month that the FDA don\u2019t do the right thing, people drop dead on the streets. What they do has a direct impact on the mortality rate from opioids in this country.\u201d\n\nBrown, an anesthesiologist who chairs the FDA committee of specialists advising the agency on whether to approve new opioid painkillers, said he no longer had confidence in repeated assurances by the FDA leadership that it was taking the epidemic seriously and prepared to put public health above the commercial interests of drug makers.\n\nUS regions where drug companies marketed hit hardest by opioids crisis Read more\n\n\u201cI think that the FDA has learned nothing. The modus operandi of the agency is that they talk a good game and then nothing happens. Working directly with the agency for the last five years, as I sit and listen to them in meetings, all I can think about is the clock ticking and how many people are dying every moment that they\u2019re not doing anything,\u201d he said. \u201cThe lack of insight that continues to be exhibited by the agency is in many ways a willful blindness that borders on the criminal.\u201d\n\nBrown\u2019s comments echo criticisms by US senators who have condemned the FDA for what they say is its \u201ccomplicity\u201d in the epidemic, for approving the powerful painkillers that drove the crisis and then failing to use its powers to protect the public as the death toll escalated.\n\nFour US senators wrote to the head of the FDA, Dr Scott Gottlieb, late last year urging him not to allow Dsuvia, a powerful opioid pill, on to the market because it was \u201cto the detriment of public health\u201d.\n\nDsuvia is a branded narcotic sufentanil pill, a more potent version of fentanyl, made by Californian pharmaceutical company AcelRx. The signatories included Senator Joe Manchin of West Virginia, whose state has the highest rate of opioid overdose deaths in the country.\n\n\u201cThis puzzling and unacceptable course of events is unfortunately reminiscent of previous FDA processes and practices that contributed to the opioid epidemic,\u201d the letter said.\n\nThe FDA\u2019s credibility has been badly damaged by the opioid crisis amid accusations that at times it behaved less as a regulator overseeing the pharmaceutical industry than a business partner of drug manufacturers. The agency helped unleash the epidemic two decades ago when it approved the sale of a high strength narcotic pill, OxyContin, as safer and more effective than other painkillers on the say so of the manufacturer, Purdue Pharma, and without requiring clinical trials. Since then the FDA has approved other opioids for wide prescribing even as evidence mounted the drugs were addictive, open to abuse and often not effective for long-term use.\n\nThe FDA was also embarrassed by revelations that officials responsible for opioid approvals were taking part in \u201cpay to play\u201d schemes in which manufacturers paid to attend meetings to draw up the criteria for approving prescription narcotics.\n\nDonald Trump\u2019s opioid commission identified the failure of the FDA and other federal institutions to properly regulate opioids and their manufacturers as an important factor in the epidemic.\n\nAfter Trump appointed Gottlieb, the new FDA chief admitted the agency \u201cdidn\u2019t get ahead\u201d of the crisis and promised \u201cdramatic\u201d action. He said he favoured examining not only whether an opioid worked but whether it was needed and whether the risks of it feeding the epidemic outweighed benefits for patients.\n\nBut that commitment has been called into question by the slow pace of introducing new practices and regulations \u2013 and by the approval of Dsuvia, a potent pill developed with the US defense department.\n\nAn advisory committee rejected the drug in 2017 over safety concerns. The senators said that they were \u201cdeeply troubled\u201d that when Dsuvia was resubmitted for consideration the following year, the FDA excluded members of the agency\u2019s drug safety committee from the hearing. The senators also said they were concerned because the decision was made when Brown, a strong critic of Dsuvia, was absent at a professional conference in San Francisco.\n\n\u201cThere\u2019s no question in my mind right that they did that on purpose,\u201d he said. \u201cThe FDA has a lack of transparency. They use the advisory committees as cover.\u201d\n\nThe FDA is not required to follow the decisions of its advisory committees but has been wary of going against their decisions since 2012, when the agency created a political storm by overruling a decision to reject Zohydro, an opioid 10 times more powerful than regular painkillers.\n\nDoctors and specialists on the committee questioned the safety of the drug and the need for it given the epidemic. The senior FDA official at the hearing, Dr Bob Rappaport, who was head of the agency\u2019s opioid approval division, angered other members by telling them there had to be \u201ca level playing field for business\u201d, which was widely interpreted as putting the right of pharmaceutical companies to make money ahead of public health.\n\nBrown described a breakdown in confidence and trust between his advisory committee and FDA officials responsible for opioid approvals. He characterized them as out of touch with the consequences of the epidemic and locked into a view promoted by drugmakers that those who become hooked are to blame for their addiction not the pills or prescribing practices.\n\nBrown blamed the problem in part on \u201ccozy, cozy relationships between the pharmaceutical industry and various parts of the FDA\u201d. Since a change to the FDA\u2019s funding in the 1990s, the agency division responsible for opioid approvals relies on the drug industry for 75% of its budget. The agency denies the money buys influence.\n\nThe FDA declined to respond to Brown\u2019s specific criticisms.\n\nGottlieb has previously defended Dsuvia by saying it is required for use in circumstances where other drugs cannot be administered, such as a battlefield. The FDA chief promised \u201cvery tight restrictions\u201d on its distribution to stop the drug appearing on the illicit market. He insisted the FDA had \u201clearned much from the harmful impact\u201d that prescription opioids have had.\n\nBut Brown remains skeptical.\n\n\u201cNothing is fundamentally being done to effect change in the regulation of opioids. If the FDA continues to encourage the pharmaceutical industry to turn out opioid after opioid after opioid, and the regulation of those opioids is no better than it was in 1995, then we\u2019ll be cleaning this up for a long time,\u201d said Brown.\n\nChris McGreal is the author of American Overdose: The Opioid Tragedy in Three Acts",
    "source_url": "www.theguardian.com",
    "bias_text": "left",
    "ID": "xuAdArdSmLvoeH2b"
}